There are currently 1248 clinical trials in Seattle, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center and University of Washington Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT03779854
Recruiting
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.
Gender:
ALL
Ages:
Between 6 months and 26 years
Trial Updated:
04/21/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blasts Under 25 Percent of Bone Marrow Nucleated Cells, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Burkitt Leukemia, Chronic Monocytic Leukemia, Lymphoblastic Lymphoma, Mast Cell Leukemia, Myeloproliferative Neoplasm
Register for Updates
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
NCT04635891
Recruiting
The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. M... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/21/2025
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: FSHD
Register for Updates
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
NCT06046495
Recruiting
This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations，uncommon mutations, classical mutations (Ex19del and L858R), and drug-resistant mutation (T790M). Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Swedish Health Sciences, Seattle, Washington +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06307795
Recruiting
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Research Site, Seattle, Washington
Conditions: Locally Advanced or Metastatic Solid Tumors
Register for Updates
A Trial to Improve Family Clinical Note Access and Outcomes for Hospitalized Children
NCT06722378
Recruiting
This study will test if giving parents access to their child's medical notes on a bedside tablet: * helps them get more involved in their care * helps identify safety concerns Parents of hospitalized children will be randomly assigned to either use the Bedside Notes tool or follow usual care. To see if this approach improves care and safety, researchers will measure: * note access * parent-reported safety concerns * overall experiences
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Hospitalized Child, Pediatric Patient Safety, Medical Errors, Parental Engagement in Care, Inpatient Pediatric Care
Register for Updates
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
NCT05005975
Recruiting
To evaluate the long-term safety and tolerability of oral dersimelagon.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
04/20/2025
Locations: University of Washington-Seattle Cancer Care Alliance, Seattle, Washington
Conditions: EPP, XLP
Register for Updates
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates
Nephrotic Syndrome Study Network
NCT01209000
Recruiting
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not s... Read More
Gender:
ALL
Ages:
80 years and below
Trial Updated:
04/18/2025
Locations: Seattle Children's Hospital, Seattle, Washington +1 locations
Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Register for Updates
TVMR With the Innovalve System Trial - Early Feasibility Study
NCT04919980
Recruiting
Study to evaluate the safety and performance of the Innovalve mitral valve replacement system
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Swedish Medical Center, Seattle, Washington
Conditions: Mitral Valve Regurgitation (Degenerative or Functional)
Register for Updates
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
NCT05727878
Recruiting
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Principal Investigator, Seattle, Washington
Conditions: Persistent Corneal Epithelial Defect
Register for Updates
IVIG for Infection Prevention After CAR-T-Cell Therapy
NCT05952804
Recruiting
This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's immu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Hematologic Malignancies
Register for Updates
Down Syndrome Obstructive Sleep Apnea
NCT06043440
Recruiting
The purpose of this study is to assess whether oxygen supplementation during sleep improves working memory and other clinical and patient-reported outcomes among children who have Down Syndrome (DS) with moderate to severe Obstructive Sleep Apnea (OSA).
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
04/18/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Down Syndrome, Obstructive Sleep Apnea
Register for Updates